• Kaken Pharmaceutical posted Q1 net sales of JPY 30.15 billion, up 59.8% year-on-year.
• Operating profit returned to profit at JPY 10.9 billion; ordinary profit returned to profit at JPY 11.26 billion.
• Profit attributable to owners of the parent swung to JPY 8.44 billion; basic EPS was JPY 222.86.
• For the year ending March 31, 2027, it reaffirmed forecasts for net sales of JPY 89.9 billion and profit attributable to owners of the parent of JPY 6.5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kaken Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.